PubMed Health⌕ Search

Biomedical subjects

M Ochoa

Publications and source records attributed to M Ochoa.

49 records · Page 3Linked to original sources
PubMed1979

Cervix cancer: treatment with combination vincristine and high doses of methotrexate.

Patients with carcinoma of the cervix (31) and of the vulva (2) were treated with high doses of Methotrexate. The objective response rate was 17% with a median duration of 3 months. Three toxic deaths occurred. The response rate of high dose methotrexate in advanced and prior treated cervix cancer does not differ from that reported in prior studies with conventional doses of intravenous methotrexate.

Adult↗
PubMed1977

Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.

This is a prelimianry report of an effort to treat women with advanced (Stage III and IV) ovarian cancer who had progressive disease in spite of previous surgery, chemotherapy and/or radiation by a program of reductive surgery, intensive immune stimulation and combination chemotherapy. An initial laparotomy was done where possible to reduce tumor burden, and then all patients were given intravenous corynebacterium parvum (C.P.) in escalating doses over a 10- to 14-day period. Cyclic chemotherapy with Cytoxan, adriamycin and 5-fluorouracil (CAF) was started and repeated monthly. Maintenance subcutaneous C.P. was given weekly. All patients had frequent follow-up clinical and laboratory examination. Immune function was measured by skin tests and in vitro tests prior to treatment and periodically during therapy. Two-thirds of the patients had depressed DNCB and PHA stimulation responses prior to treatment, and almost all had severely depressed lymphocyte counts. Thirty-nine patients entered the program. Exploratory laparotomy was done in 16 patients and in eight, successful tumor reduction was accomplished. Eleven patients received intravenous C. Parvum and all expired before receiving chemotherapy. Four patients received C. Parvum and less than three cycles of CAF; all expired within 2 months. Twenty-four patients received C. Parvum and less than or equal to three cycles of CAF. Four patients had complete regression of measurable disease and were living free of disease 9-12 months after starting CAF. Eight patients had more than 50% regression for a minimum of 3 months, and five were living with disease (LWD) 5-11 months. Five patients had 25% to 50% regression and three were LWD 4-8 months. Seven patients had no regression and all expired within 4 months. Of eight patients who had successful reductive surgery prior to treatment, three were free of disease, median of 10 months, and five had partial responses and were living with disease, a median of 9 months. Although pre-treatment immune function was better in the patients who had a good response to CP and CAF (10 of 12 were DNCB+) vs that in patients with a poor response (4 of 12 were DNCB+) immune function was not significantly improved during therapy. The initial treatment results in this program are encouraging and suggest that this approach may be useful in patients with earlier disease.

Adult↗
PubMed1976

Treatment of cancer of the ovary.

This chapter has stressed the importance of early diagnosis in the treatment of cancer of the ovary with suggestions as to achieving this goal by a more aggressive approach to the accurate diagnosis of pelvic tumours. The combined use of surgery with radiation therapy and/or chemotherapy has also been discussed with the definition of the functions of the surgeon, radiotherapist and chemotherapist. The place of surgery in the staging and initial treatment of this disease is outlined and the indications for surgery for advanced and recurrent disease are demonstrated. The use of the various modalities of ionising radiation has been outlined and the place of chemotherapy and selection of appropriate drugs are also discussed.

Alkylating Agents↗
PubMedDate not supplied

Contribution of the ventricles and the atrial appendages to the elevation of plasma atrial natriuretic factor (ANF) during pacing-induced heart failure in conscious dogs.

The goal of our study was to determine whether the elevation in plasma ANF was produced by the atrial appendages or ventricular tissue during pacing-induced heart failure in chronically instrumented conscious dogs (sham) or dogs with bilateral atrial appendectomy. Acute volume expansion caused a significant elevation of plasma ANF from 80 +/- 8 to 149 +/- 26 pg/ml (p < 0.01) in sham dogs, but caused no significant change from 67 +/- 7 to 84 +/- 8 pg/ml in atrial appendectomized dogs. There were increases in left ventricular end-diastolic pressure (LVEDP) and left atrial pressure (LAP) in both groups of dogs. After rapid left ventricular pacing (210-240 beats/min) for 4 weeks to induce heart failure, dogs in both groups had tachycardia, elevated LVEDP and higher LAP. Plasma ANF was increased by 250% to 283 +/- 64 pg/ml (p < 0.01) in sham dogs, and only 40% to 94 +/- 15 pg/ml (p > 0.05) in atrial appendectomized dogs. In response to volume expansion, there were further increases in LVEDP and LAP in both groups of dogs, but plasma ANF was not elevated (288 +/- 39 pg/ml) in sham dogs and only slightly increased (132 +/- 7 pg/ml) in atrial appendectomized dogs. Our results suggest that, during pacing-induced heart failure, the atrial appendages are the major source of elevated plasma ANF, and the remaining atrial and ventricular tissue, even when maximally stretched, can only modestly increase plasma ANF.

Animals↗